Acute arsenic poisoning: absence of polyneuropathy after treatment with 2,3-dimercaptopropanesulphonate (DMPS)
| Autor: | D F Moore, I M House, G Berlyne, H A Davies, Christopher A. O’Callaghan, J A Henry, C S Ogg |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Nausea Arsenic poisoning Gastroenterology chemistry.chemical_compound Internal medicine Arsenic Poisoning medicine Humans Arsenic trioxide business.industry Dimercaprol Neurotoxicity Peripheral Nervous System Diseases Unithiol medicine.disease Psychiatry and Mental health Endocrinology chemistry Acute Disease Toxicity Vomiting Surgery Neurology (clinical) medicine.symptom business Polyneuropathy Research Article medicine.drug |
| Popis: | Two men aged 19 and 21 years ingested 1 g and 4 g respectively from 3 kg of a white crystalline powder that they thought was a substance of abuse. It was later identified as almost pure arsenic trioxide. Both had nausea and vomiting and one developed acute renal failure. Each was treated with 2,3-dimercaptopropanesulphonate (DMPS), and made a full recovery with no evidence of prolonged renal or neurological impairment. The DMPS-arsenic complex is probably associated with lower penetration into the CNS and as a consequence treatment with DMPS may result in lower acute and chronic neurotoxicity than treatment with the currently standard recommended chelating agent dimercaprol (British Anti-Lewisite; BAL). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|